Alphatec (NASDAQ:ATEC) Shares Down 6.6% on Insider Selling

Alphatec Holdings, Inc. (NASDAQ:ATEC) traded down 6.6% during trading on Monday after an insider sold shares in the company. The company traded as low as $10.44 and last traded at $10.62. 327,314 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 1,717,581 shares. The stock had previously closed at $11.36.

Specifically, COO Scott Lish sold 27,453 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now directly owns 867,677 shares of the company’s stock, valued at approximately $9,969,608.73. This represents a 3.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Patrick Miles sold 43,459 shares of Alphatec stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $11.95, for a total transaction of $519,335.05. Following the transaction, the chief executive officer now directly owns 6,065,772 shares in the company, valued at $72,485,975.40. This represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Alphatec news, EVP David Sponsel sold 36,256 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the sale, the executive vice president now owns 735,074 shares in the company, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Analysts Set New Price Targets

Several research firms have recently issued reports on ATEC. Needham & Company LLC upped their target price on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays boosted their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

Alphatec Stock Performance

The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a 50 day simple moving average of $10.31 and a 200-day simple moving average of $8.10. The stock has a market capitalization of $1.55 billion, a P/E ratio of -8.55 and a beta of 1.43.

Institutional Investors Weigh In On Alphatec

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Alphatec by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company’s stock worth $54,795,000 after purchasing an additional 47,797 shares during the period. American Century Companies Inc. boosted its holdings in Alphatec by 36.5% in the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock worth $45,800,000 after buying an additional 1,334,780 shares during the period. State Street Corp grew its stake in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after buying an additional 287,350 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after acquiring an additional 297,850 shares during the period. Finally, Emerald Advisers LLC lifted its position in shares of Alphatec by 112.4% during the fourth quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company’s stock worth $13,366,000 after acquiring an additional 770,586 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.